Daniel Patrick O’day Sells 15,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the sale, the chief executive officer owned 617,567 shares of the company’s stock, valued at approximately $81,185,357.82. This represents a 2.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O’day also recently made the following trade(s):

• On Tuesday, April 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $129.16, for a total value of $1,291,600.00.

Gilead Sciences Stock Performance

Gilead Sciences stock traded down $3.53 during mid-day trading on Tuesday, reaching $127.57. 8,078,680 shares of the company were exchanged, compared to its average volume of 6,782,675. The firm’s 50-day simple moving average is $135.10 and its two-hundred day simple moving average is $134.26. Gilead Sciences, Inc. has a twelve month low of $104.46 and a twelve month high of $157.29. The firm has a market cap of $158.39 billion, a PE ratio of 17.38 and a beta of 0.31. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. During the same quarter in the prior year, the business earned $1.81 earnings per share. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities analysts predict that Gilead Sciences, Inc. will post -0.79 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be given a dividend of $0.82 per share. The ex-dividend date is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.6%. Gilead Sciences’s dividend payout ratio is presently 44.69%.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in shares of Gilead Sciences by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after acquiring an additional 2,113,692 shares in the last quarter. State Street Corp grew its position in shares of Gilead Sciences by 1.9% in the fourth quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company’s stock valued at $7,393,921,000 after purchasing an additional 1,151,213 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Gilead Sciences by 4.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company’s stock worth $3,399,734,000 after purchasing an additional 1,195,269 shares in the last quarter. Bank of America Corp DE raised its position in shares of Gilead Sciences by 15.2% during the 4th quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock worth $2,837,948,000 after purchasing an additional 3,046,688 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Gilead Sciences during the 4th quarter worth approximately $2,617,152,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported positive Phase 3 IDEAL trial results for Livdelzi in PBC, showing statistically significant ALP normalization versus placebo, which supports the drug’s commercial potential. Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
• Positive Sentiment: Long-term ASSURE study findings for Livdelzi showed sustained efficacy and safety, reinforcing confidence in Gilead’s liver-disease franchise. Gilead Sciences, Inc. (GILD) Gains Attention as Livdelzi Demonstrates Long-Term Efficacy and Safety
• Positive Sentiment: RBC Capital upgraded Gilead from “hold” to “moderate buy,” a sign that analysts see improving upside for the shares. RBC Capital Reiterates Sector Perform Rating on Gilead Sciences (GILD)
• Positive Sentiment: Cencora announced support for U.S. distribution of Kite’s CAR T therapies, including Yescarta and Tecartus, which supports Gilead’s cell-therapy commercial infrastructure. Cencora to Support U.S. Distribution of Kite’s CAR T-Cell Therapies

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on GILD shares. Weiss Ratings lowered shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday. TD Cowen raised their price objective on shares of Gilead Sciences from $145.00 to $160.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Jefferies Financial Group began coverage on Gilead Sciences in a research report on Tuesday, March 10th. They set a “buy” rating and a $180.00 target price on the stock. Deutsche Bank Aktiengesellschaft increased their target price on Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Finally, Sanford C. Bernstein reissued an “outperform” rating and issued a $160.00 price target on shares of Gilead Sciences in a report on Wednesday, February 11th. Twenty-six investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $156.93.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.